Strain Name:

FVB/N-Tg(MMTVneu)202Mul/J

Stock Number:

002376

Availability:

Level 3

Use Restrictions Apply, see Terms of Use

Description

Strain Information

Type Mutant Strain; Transgenic;
Additional information on Genetically Engineered Mutant Mice.
Mating SystemHomozygote x Homozygote         (Female x Male)
Specieslaboratory mouse
GenerationF?+32 (20-DEC-06)
 
Donating Investigator William Muller,   McGill University

Appearance
albino
Related Genotype: Tyrc/Tyrc

Description
Mice homozygous for the MMTVneu (rat) transgene are viable and fertile. There is no phenotypic effect in males. The transgene is expressed at low levels in normal mammary epithelium, salivary gland, and lung. Higher expression is detected in tumor tissue. Focal mammary tumors first appear at 4 months, with a median incidence of 205 days. Both virgin and breeder mice develop tumors. Tumors arise as foci in hyperplastic, dysplastic mammary glands. Seventy-two percent of tumor-bearing mice that live to 8 months or longer develop metastatic disease to the lung. The phenotype of MMTV/unactivated neu transgenic mice differs from that of the MMTV/activated neu produced by Phil Leder, in which multifocal tumors involving the entire mammary epithelium arise.

Control Information

  Control
   001800 FVB/NJ
   FVB/NJ (Stock No. 001800) mice may be used as controls.
 
  Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of Erbb2
005038   FVB-Tg(MMTV-Erbb2)NK1Mul/J
View Strains carrying other alleles of Erbb2     (1 strain)

View Strains carrying other alleles of MMTV     (18 strains)

Additional Web Information

Genetic Quality Control Annual Report

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

View Mammalian Phenotype Terms

Mammalian Phenotype Terms
      assigned by genotype

Tg(MMTVneu)202Mul/0

        involves: FVB/N
  • tumorigenesis
  • mammary gland tumor (MGI Ref ID J:35344)
    • in 35% of female mice at day 250
    • mammary adenocarcinoma (MGI Ref ID J:80974)

Tg(MMTVneu)202Mul/0

        FVB/N-Tg(MMTVneu)202Mul
  • tumorigenesis
  • increased metastatic potential (MGI Ref ID J:56332)
    • 72% of the tumor-bearing mice that lived to an age of 8 months or older developed metastases to the lung
    • multiple foci of metastatic mammary adenocarcinoma lodged in pulmonary vessels were observed
  • mammary adenocarcinoma (MGI Ref ID J:56332)
    • 50% incidence observed in both virgin and non-virgin females by 205 days of age; males appear phenotypically normal
    • focal adenocarcinomas surrounded by hyperplastic mammary epithelium
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cancer Research
Increased Tumor Incidence (Mammary Gland Tumors)
Oncogenes

Genes & Alleles

Gene & Allele Information

Allele Symbol Tg(MMTVneu)202Mul
Allele Name transgene insertion 202, William Muller
Allele Type Transgenic (random, expressed)
Common Name(s) HER-2/neu; MMTV-c-Neu; MMTV-neu; MMTVneu; MUC1.Tg; NeuT+; TgN (MMTV-neu); erb-B-2; neu-N;
Mutation Made By William Muller,   McGill University
Strain of OriginFVB/N
Expressed Gene Erbb2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian), rat
Promoter MMTV, Mouse Mammary Tumor Virus, MMTV
General Note Multiple transgenic lines were produced, including 202, 169, 510, 721, and 732.

In mice carrying both this transgene and Tg(Trp53R172H)8512Jmr, mammary tumors are first observed after two rounds of pregnancy and lactation at 112 days; the median latency was 154 days. All mice developed mammary tumors before 200 days of age. The neoplasms are of high grade and growth fraction, indicated by variable nuclear and cytological morphology, anaplasia, aneuploidy, and higher rates of mitosis and apoptosis. Metastatic incidence was not reported.

In virgin mice carrying both this transgene and Tg(MMTVTGFA)29Rjc,the mammary trees show extensive lobuloalveolar development comparable to a normal FVB lactating mouse. The alveoli of the bitransgenic mice have a denser cell lining in the walls. Their mammary glands are characterized by epithelial hyperplasia and dysplasia with stromal inflammation. In virgin mice, mammary tumors first arise at about 100 days; the median latency is approximately 180 days. Tumors are multifocal and involve the entire mammary epithelium. Metastatic incidence was not reported.

Molecular Note This transgene has the wild-type form of the rat gene. The transgene consists of an MMTV promoter, an unactivated rat Erbb2 cDNA sequence, and SV40 polyadenylation and splicing signals. Transgene expression was detected in the mammary gland in 5 out of 6transgenic lines as determined by RNase protection assay. Low levels of transgene transcript were also detected in the salivary gland, spleen, thymus, and lung. [MGI Ref ID J:56332]

Genotyping

Genotyping Information

Genotyping Protocols

Tg(MMTVneu)202Mul, QPCR, vers. 3
Tg(MMTVneu)202Mul, STD PCR, vers. 2

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Guy CT; Webster MA; Schaller M; Parsons TJ; Cardiff RD; Muller WJ. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89(22):10578-82. [PubMed: 1359541]  [MGI Ref ID J:56332]

Muller WJ; Arteaga CL; Muthuswamy SK; Siegel PM; Webster MA; Cardiff RD; Meise KS; Li F; Halter SA; Coffey RJ. 1996. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16(10):5726-36. [PubMed: 8816486]  [MGI Ref ID J:35344]

Additional References

Bowe DB; Kenney NJ; Adereth Y; Maroulakou IG. 2002. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 21(2):291-8. [PubMed: 11803472]  [MGI Ref ID J:74381]

Cuadros C; Dominguez AL; Frost GI; Borgstrom P; Lustgarten J. 2003. Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice. Cancer Res 63(18):5895-901. [PubMed: 14522915]  [MGI Ref ID J:86072]

Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH. 2003. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95(24):1825-33. [PubMed: 14679152]  [MGI Ref ID J:87515]

Moadel RM; Nguyen AV; Lin EY; Lu P; Mani J; Blaufox MD; Pollard JW; Dadachova E. 2003. Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer. Breast Cancer Res 5(6):R199-205. [PubMed: 14580255]  [MGI Ref ID J:86497]

Muraoka RS; Koh Y; Roebuck LR; Sanders ME; Brantley-Sieders D; Gorska AE; Moses HL; Arteaga CL. 2003. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 23(23):8691-703. [PubMed: 14612410]  [MGI Ref ID J:87030]

Rego EM; Wang ZG; Peruzzi D; He LZ; Cordon-Cardo C; Pandolfi PP. 2001. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med 193(4):521-29. [PubMed: 11181703]  [MGI Ref ID J:67484]

Wu K; Zhang Y; Xu XC; Hill J; Celestino J; Kim HT; Mohsin SK; Hilsenbeck SG; Lamph WW; Bissonette R; Brown PH. 2002. The Retinoid X Receptor-Selective Retinoid, LGD1069, Prevents the Development of Estrogen Receptor-Negative Mammary Tumors in Transgenic Mice. Cancer Res 62(22):6376-80. [PubMed: 12438218]  [MGI Ref ID J:80300]

Yang X; Edgerton SM; Kosanke SD; Mason TL; Alvarez KM; Liu N; Chatterton RT; Liu B; Wang Q; Kim A; Murthy S; Thor AD. 2003. Hormonal and Dietary Modulation of Mammary Carcinogenesis in Mouse Mammary Tumor Virus-c-erbB-2 Transgenic Mice. Cancer Res 63(10):2425-33. [PubMed: 12750262]  [MGI Ref ID J:83495]

Tg(MMTVneu)202Mul related

Acevedo R; Parnell PG; Villanueva H; Chapman LM; Gimenez T; Gray SL; Baldwin WS. 2005. The contribution of hepatic steroid metabolism to serum estradiol and estriol concentrations in nonylphenol treated MMTVneu mice and its potential effects on breast cancer incidence and latency. J Appl Toxicol 25(5):339-53. [PubMed: 16013040]  [MGI Ref ID J:101390]

Adriance MC; Gendler SJ. 2004. Downregulation of Muc1 in MMTV-c-Neu tumors. Oncogene 23(3):697-705. [PubMed: 14737104]  [MGI Ref ID J:88101]

Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT. 2007. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 179(1):472-82. [PubMed: 17579068]  [MGI Ref ID J:125804]

Alli PM; Pinn ML; Jaffee EM; McFadden JM; Kuhajda FP. 2005. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24(1):39-46. [PubMed: 15489885]  [MGI Ref ID J:95289]

Andrechek ER; Laing MA; Girgis-Gabardo AA; Siegel PM; Cardiff RD; Muller WJ. 2003. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res 63(16):4920-6. [PubMed: 12941816]  [MGI Ref ID J:85139]

Anisimov VN; Berstein LM; Egormin PA; Piskunova TS; Popovich IG; Zabezhinski MA; Kovalenko IG; Poroshina TE; Semenchenko AV; Provinciali M; Re F; Franceschi C. 2005. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40(8-9):685-93. [PubMed: 16125352]  [MGI Ref ID J:102134]

Anisimov VN; Egormin PA; Bershtein LM; Zabezhinskii MA; Piskunova TS; Popovich IG; Semenchenko AV. 2005. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 139(6):721-3. [PubMed: 16224592]  [MGI Ref ID J:104186]

Astolfi A; Landuzzi L; Nicoletti G; De Giovanni C; Croci S; Palladini A; Ferrini S; Iezzi M; Musiani P; Cavallo F; Forni G; Nanni P; Lollini PL. 2005. Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. Am J Pathol 166(4):1205-16. [PubMed: 15793299]  [MGI Ref ID J:97061]

Astolfi A; Rolla S; Nanni P; Quaglino E; De Giovanni C; Iezzi M; Musiani P; Forni G; Lollini PL; Cavallo F; Calogero RA. 2005. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. Cancer Immunol Immunother 54(6):599-610. [PubMed: 15690207]  [MGI Ref ID J:97899]

Benezra R; Henke E; Ciarrocchi A; Ruzinova M; Solit D; Rosen N; Nolan D; Mittal V; de Candia P. 2005. Induction of complete regressions of oncogene-induced breast tumors in mice. Cold Spring Harb Symp Quant Biol 70:375-81. [PubMed: 16869774]  [MGI Ref ID J:115183]

Bershtein LM; Alimova IN; Tsyrlina EV; Anisimov VN. 2003. Mammary Tumors in HER-2/NEU Mice Are Characterized by Low Content of Estrogen Receptors-alpha and Absence of Progesterone Receptors. Bull Exp Biol Med 135(6):580-1. [PubMed: 12937679]  [MGI Ref ID J:85686]

Boggio K; Di Carlo E; Rovero S; Cavallo F; Quaglino E; Lollini PL; Nanni P; Nicoletti G; Wolf S; Musiani P; Forni G. 2000. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 60(2):359-64. [PubMed: 10667588]  [MGI Ref ID J:60215]

Boggio K; Nicoletti G; Di Carlo E; Cavallo F; Landuzzi L; Melani C; Giovarelli M; Rossi I; Nanni P; De Giovanni C; Bouchard P; Wolf S; Modesti A; Musiani P; Lollini PL; Colombo MP; Forni G. 1998. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188(3):589-96. [PubMed: 9687535]  [MGI Ref ID J:49500]

Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J. 2008. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118(1):64-78. [PubMed: 18079969]  [MGI Ref ID J:130805]

Cao Y; Luo JL; Karin M. 2007. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A 104(40):15852-7. [PubMed: 17890319]  [MGI Ref ID J:125555]

Cardiff RD; Anver MR; Gusterson BA; Hennighausen L; Jensen RA; Merino MJ; Rehm S; Russo J; Tavassoli FA; Wakefield LM; Ward JM; Green JE. 2000. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting [see comments] Oncogene 19(8):968-88. [PubMed: 10713680]  [MGI Ref ID J:61035]

Cardiff RD; Munn RJ. 1995. Comparative pathology of mammary tumorigenesis in transgenic mice. Cancer Lett 90(1):13-9. [PubMed: 7720037]  [MGI Ref ID J:72081]

Carothers AM; Moran AE; Cho NL; Redston M; Bertagnolli MM. 2006. Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res 66(12):6432-8. [PubMed: 16778222]  [MGI Ref ID J:110102]

Chan T; Sami A; El-Gayed A; Guo X; Xiang J. 2006. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Ther 13(19):1391-402. [PubMed: 16724093]  [MGI Ref ID J:115815]

Chiodoni C; Iezzi M; Guiducci C; Sangaletti S; Alessandrini I; Ratti C; Tiboni F; Musiani P; Granger DN; Colombo MP. 2006. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 203(11):2441-50. [PubMed: 17043144]  [MGI Ref ID J:118175]

Cleary MP; Grande JP; Juneja SC; Maihle NJ. 2004. Diet-Induced Obesity and Mammary Tumor Development in MMTV-neu Female Mice. Nutr Cancer 50(2):174-80. [PubMed: 15623464]  [MGI Ref ID J:96292]

D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG. 2003. The Role of Ink4a/Arf in ErbB2 Mammary Gland Tumorigenesis. Cancer Res 63(12):3395-402. [PubMed: 12810676]  [MGI Ref ID J:83972]

Davies MP; Rudland PS; Robertson L; Parry EW; Jolicoeur P; Barraclough R. 1996. Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 13(8):1631-7. [PubMed: 8895508]  [MGI Ref ID J:53489]

Davis VL; Jayo MJ; Ho A; Kotlarczyk MP; Hardy ML; Foster WG; Hughes CL. 2008. Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. Cancer Res 68(20):8377-83. [PubMed: 18922910]  [MGI Ref ID J:140554]

Di Carlo E; Diodoro MG; Boggio K; Modesti A; Modesti M; Nanni P; Forni G; Musiani P. 1999. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 79(10):1261-9. [PubMed: 10532589]  [MGI Ref ID J:58098]

Ercolini AM; Ladle BH; Manning EA; Pfannenstiel LW; Armstrong TD; Machiels JP; Bieler JG; Emens LA; Reilly RT; Jaffee EM. 2005. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201(10):1591-602. [PubMed: 15883172]  [MGI Ref ID J:101130]

Esserman LJ; Lopez T; Montes R; Bald LN; Fendly BM; Campbell MJ. 1999. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother 47(6):337-42. [PubMed: 10203064]  [MGI Ref ID J:54329]

Facciponte JG; Wang XY; Subjeck JR. 2007. Hsp110 and Grp170, members of the Hsp70 superfamily, bind to scavenger receptor-A and scavenger receptor expressed by endothelial cells-I. Eur J Immunol 37(8):2268-79. [PubMed: 17615582]  [MGI Ref ID J:123549]

Fereshteh MP; Tilli MT; Kim SE; Xu J; O'Malley BW; Wellstein A; Furth PA; Riegel AT. 2008. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res 68(10):3697-706. [PubMed: 18483252]  [MGI Ref ID J:135022]

Freitas I; Boncompagni E; Vaccarone R; Fenoglio C; Barni S; Baronzio GF. 2007. Iron accumulation in mammary tumor suggests a tug of war between tumor and host for the microelement. Anticancer Res 27(5A):3059-65. [PubMed: 17970045]  [MGI Ref ID J:133602]

Freitas I; Fracchiolla S; Baronzio G; Griffini P; Bertone R; Sitar GM; Barni S; Gerzeli G; Sacco MG. 2003. Stem cell recruitment and liver de-differentiation in MMTV-neu (ErbB-2) transgenic mice. Anticancer Res 23(5A):3783-94. [PubMed: 14666678]  [MGI Ref ID J:87525]

Gerloni M; Castiglioni P; Zanetti M. 2005. The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice. J Immunol 175(10):6551-9. [PubMed: 16272309]  [MGI Ref ID J:119394]

Henry MD; Triplett AA; Oh KB; Smith GH; Wagner KU. 2004. Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice. Oncogene 23(41):6980-5. [PubMed: 15286714]  [MGI Ref ID J:93776]

Hewitt SC; Bocchinfuso WP; Zhai J; Harrell C; Koonce L; Clark J; Myers P; Korach KS. 2002. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Cancer Res 62(10):2798-805. [PubMed: 12019156]  [MGI Ref ID J:76653]

Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ. 2002. Celecoxib, a Selective Cyclooxygenase 2 Inhibitor, Protects against Human Epidermal Growth Factor Receptor 2 (HER-2)/neu-induced Breast Cancer. Cancer Res 62(19):5405-7. [PubMed: 12359744]  [MGI Ref ID J:79691]

Huang S; Li Y; Chen Y; Podsypanina K; Chamorro M; Olshen AB; Desai KV; Tann A; Petersen D; Green JE; Varmus HE. 2005. Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice. Genome Biol 6(10):R84. [PubMed: 16207355]  [MGI Ref ID J:103821]

Hulit J; Lee RJ; Li Z; Wang C; Katiyar S; Yang J; Quong AA; Wu K; Albanese C; Russell R; Di Vizio D; Koff A; Thummala S; Zhang H; Harrell J; Sun H; Muller WJ; Inghirami G; Lisanti MP; Pestell RG. 2006. p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/{beta}-Catenin Signaling. Cancer Res 66(17):8529-41. [PubMed: 16951165]  [MGI Ref ID J:113389]

Husemann Y; Geigl JB; Schubert F; Musiani P; Meyer M; Burghart E; Forni G; Eils R; Fehm T; Riethmuller G; Klein CA. 2008. Systemic spread is an early step in breast cancer. Cancer Cell 13(1):58-68. [PubMed: 18167340]  [MGI Ref ID J:131063]

Jackson-Fisher AJ; Bellinger G; Shum E; Duong JK; Perkins AS; Gassmann M; Muller W; Kent Lloyd KC; Stern DF. 2006. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene 25(41):5664-72. [PubMed: 16652155]  [MGI Ref ID J:115842]

Jager R; Friedrichs N; Heim I; Buttner R; Schorle H. 2005. Dual role of AP-2gamma in ErbB-2-induced mammary tumorigenesis. Breast Cancer Res Treat 90(3):273-80. [PubMed: 15830141]  [MGI Ref ID J:98654]

Jin Z; MacDonald RS. 2002. Soy isoflavones increase latency of spontaneous mammary tumors in mice. J Nutr 132(10):3186-90. [PubMed: 12368416]  [MGI Ref ID J:79685]

Kaminski R; Zagozdzon R; Fu Y; Mroz P; Fu W; Seng S; Avraham S; Avraham HK. 2006. Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice. Cancer Res 66(11):5757-62. [PubMed: 16740714]  [MGI Ref ID J:110109]

Kmieciak M; Morales JK; Morales J; Bolesta E; Grimes M; Manjili MH. 2008. Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design. Cancer Immunol Immunother 57(9):1391-8. [PubMed: 18278493]  [MGI Ref ID J:139821]

Knutson KL; Dang Y; Lu H; Lukas J; Almand B; Gad E; Azeke E; Disis ML. 2006. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177(1):84-91. [PubMed: 16785502]  [MGI Ref ID J:114945]

Kosanke S; Edgerton SM; Moore D 2nd; Yang X; Mason T; Alvarez K; Jones L; Kim A; Thor AD. 2004. Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice. Comp Med 54(3):280-7. [PubMed: 15253274]  [MGI Ref ID J:91417]

Kouros-Mehr H; Bechis SK; Slorach EM; Littlepage LE; Egeblad M; Ewald AJ; Pai SY; Ho IC; Werb Z. 2008. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13(2):141-52. [PubMed: 18242514]  [MGI Ref ID J:131913]

Kurpios NA; Sabolic NA; Shepherd TG; Fidalgo GM; Hassell JA. 2003. Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 8(2):177-90. [PubMed: 14635793]  [MGI Ref ID J:87017]

Kurt RA; Bauck M; Harma S; Adler E; Vitiello P; Wisner KP; Tackitt S; Urba WJ. 2003. Altered chemokine receptor sensitivity in FVBN202 rat neu transgenic mice. Breast Cancer Res Treat 77(3):225-32. [PubMed: 12602922]  [MGI Ref ID J:81932]

Kurt RA; Whitaker R; Baher A; Seung S; Urba WJ. 2000. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice. Int J Cancer 87(5):688-94. [PubMed: 10925363]  [MGI Ref ID J:64150]

Kwak EL; Kim S; Zhang J; Cardiff RD; Schmidt EV; Haber DA. 2006. Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res 66(4):1923-8. [PubMed: 16488990]  [MGI Ref ID J:106663]

Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA. 2006. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene 25(23):3325-34. [PubMed: 16434967]  [MGI Ref ID J:112325]

Lanza-Jacoby S; Miller S; Flynn J; Gallatig K; Daskalakis C; Masferrer JL; Zweifel BS; Sembhi H; Russo IH. 2003. The Cyclooxygenase-2 Inhibitor, Celecoxib, Prevents the Development of Mammary Tumors in HER-2/neu Mice. Cancer Epidemiol Biomarkers Prev 12(12):1486-1491. [PubMed: 14693742]  [MGI Ref ID J:87505]

Lenferink AE; Simpson JF; Shawver LK; Coffey RJ; Forbes JT; Arteaga CL. 2000. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci U S A 97(17):9609-14. [PubMed: 10931950]  [MGI Ref ID J:64071]

Li B; Rosen JM; McMenamin-Balano J; Muller WJ; Perkins AS. 1997. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 17(6):3155-63. [PubMed: 9154814]  [MGI Ref ID J:40336]

Li Y; Welm B; Podsypanina K; Huang S; Chamorro M; Zhang X; Rowlands T; Egeblad M; Cowin P; Werb Z; Tan LK; Rosen JM; Varmus HE. 2003. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 100(26):15853-8. [PubMed: 14668450]  [MGI Ref ID J:87520]

Liby K; Rendi M; Suh N; Royce DB; Risingsong R; Williams CR; Lamph W; Labrie F; Krajewski S; Xu X; Kim H; Brown P; Sporn MB. 2006. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res 12(19):5902-9. [PubMed: 17020999]  [MGI Ref ID J:117015]

Liby K; Risingsong R; Royce DB; Williams CR; Yore MM; Honda T; Gribble GW; Lamph WW; Vannini N; Sogno I; Albini A; Sporn MB. 2008. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. Clin Cancer Res 14(14):4556-63. [PubMed: 18628471]  [MGI Ref ID J:140420]

Liu B; Edgerton S; Yang X; Kim A; Ordonez-Ercan D; Mason T; Alvarez K; McKimmey C; Liu N; Thor A. 2005. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res 65(3):879-86. [PubMed: 15705886]  [MGI Ref ID J:96381]

Lo Iacono M; Cavallo F; Quaglino E; Rolla S; Iezzi M; Pupa SM; De Giovanni C; Lollini PL; Musiani P; Forni G; Calogero RA. 2005. A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice. Int J Immunopathol Pharmacol 18(2):351-63. [PubMed: 15888257]  [MGI Ref ID J:101125]

Lollini PL; Nicoletti G; Landuzzi L; De Giovanni C; Rossi I; Di Carlo E; Musiani P; Muller WJ; Nanni P. 1998. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int J Cancer 77(6):937-41. [PubMed: 9714068]  [MGI Ref ID J:52636]

Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH. 2003. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95(24):1825-33. [PubMed: 14679152]  [MGI Ref ID J:87515]

Lu H; Knutson KL; Gad E; Disis ML. 2006. The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res 66(19):9754-61. [PubMed: 17018635]  [MGI Ref ID J:113384]

Malewicz B; Wang Z; Jiang C; Guo J; Cleary MP; Grande JP; Lu J. 2006. Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements. Carcinogenesis 27(9):1739-47. [PubMed: 16597642]  [MGI Ref ID J:113345]

Menard S; Aiello P; Tagliabue E; Rumio C; Lollini PL; Colnaghi MI; Balsari A. 2000. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res 60(2):273-5. [PubMed: 10667575]  [MGI Ref ID J:60217]

Meng X; Shoemaker SF; McGee SO; Ip MM. 2008. t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways. Carcinogenesis 29(5):1013-21. [PubMed: 18339686]  [MGI Ref ID J:138507]

Mosley JD; Poirier JT; Seachrist DD; Landis MD; Keri RA. 2007. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther 6(8):2188-97. [PubMed: 17699716]  [MGI Ref ID J:138101]

Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ. 2003. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 26(1):47-62. [PubMed: 12514429]  [MGI Ref ID J:81059]

Muller AJ; Duhadaway JB; Donover PS; Sutanto-Ward E; Prendergast GC. 2005. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11(3):312-9. [PubMed: 15711557]  [MGI Ref ID J:97114]

Muller WJ; Ho J; Siegel PM. 1998. Oncogenic activation of Neu/ErbB-2 in a transgenic mouse model for breast cancer. Biochem Soc Symp 63:149-57. [PubMed: 9513719]  [MGI Ref ID J:72137]

Muraoka RS; Koh Y; Roebuck LR; Sanders ME; Brantley-Sieders D; Gorska AE; Moses HL; Arteaga CL. 2003. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 23(23):8691-703. [PubMed: 14612410]  [MGI Ref ID J:87030]

Muraoka RS; Lenferink AE; Law B; Hamilton E; Brantley DM; Roebuck LR; Arteaga CL. 2002. ErbB2/Neu-Induced, Cyclin D1-Dependent Transformation Is Accelerated in p27-Haploinsufficient Mammary Epithelial Cells but Impaired in p27-Null Cells. Mol Cell Biol 22(7):2204-19. [PubMed: 11884607]  [MGI Ref ID J:75235]

Muraoka-Cook RS; Shin I; Yi JY; Easterly E; Barcellos-Hoff MH; Yingling JM; Zent R; Arteaga CL. 2006. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25(24):3408-23. [PubMed: 16186809]  [MGI Ref ID J:112326]

Murata S; Kominsky SL; Vali M; Zhang Z; Garrett-Mayer E; Korz D; Huso D; Baker SD; Barber J; Jaffee E; Reilly RT; Sukumar S. 2006. Ductal access for prevention and therapy of mammary tumors. Cancer Res 66(2):638-45. [PubMed: 16423990]  [MGI Ref ID J:106497]

Murata S; Ladle BH; Kim PS; Lutz ER; Wolpoe ME; Ivie SE; Smith HM; Armstrong TD; Emens LA; Jaffee EM; Reilly RT. 2006. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol 176(2):974-83. [PubMed: 16393983]  [MGI Ref ID J:126446]

Muthuswamy SK; Siegel PM; Dankort DL; Webster MA; Muller WJ. 1994. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 14(1):735-43. [PubMed: 7903421]  [MGI Ref ID J:72122]

Nair RE; Kilinc MO; Jones SA; Egilmez NK. 2006. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J Immunol 176(12):7325-34. [PubMed: 16751376]  [MGI Ref ID J:115031]

Niemeyer CC; Spencer-Dene B; Wu JX; Adamson ED. 1999. Preneoplastic mammary tumor markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice. Int J Cancer 81(4):588-91. [PubMed: 10225449]  [MGI Ref ID J:54862]

Norgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ Jr; Poulsen HS; Moses HL. 1999. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res 5(1):35-42. [PubMed: 9918200]  [MGI Ref ID J:52053]

Ostrand-Rosenberg S; Sinha P; Clements V; Dissanayake SI; Miller S; Davis C; Danna E. 2004. Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease. Cancer Immunol Immunother 53(2):86-91. [PubMed: 14593499]  [MGI Ref ID J:86509]

Pannellini T; Spadaro M; Di Carlo E; Ambrosino E; Iezzi M; Amici A; Lollini PL; Forni G; Cavallo F; Musiani P. 2006. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol 176(12):7695-703. [PubMed: 16751417]  [MGI Ref ID J:115041]

Pape-Ansorge KA; Grande JP; Christensen TA; Maihle NJ; Cleary MP. 2002. Effect of Moderate Caloric Restriction and/or Weight Cycling on Mammary Tumor Incidence and Latency in MMTV-Neu Female Mice. Nutr Cancer 44(2):162-8. [PubMed: 12734063]  [MGI Ref ID J:84226]

Park KH; Gad E; Goodell V; Dang Y; Wild T; Higgins D; Fintak P; Childs J; Dela Rosa C; Disis ML. 2008. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 68(20):8400-9. [PubMed: 18922913]  [MGI Ref ID J:140553]

Podsypanina K; Li Y; Varmus HE. 2004. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Med 2(1):24. [PubMed: 15198801]  [MGI Ref ID J:91649]

Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S. 2001. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 8(1):75-9. [PubMed: 11402305]  [MGI Ref ID J:80581]

Quaglino E; Rolla S; Iezzi M; Spadaro M; Musiani P; De Giovanni C; Lollini PL; Lanzardo S; Forni G; Sanges R; Crispi S; De Luca P; Calogero R; Cavallo F. 2004. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 113(5):709-17. [PubMed: 14991069]  [MGI Ref ID J:88661]

Reddy HK; Mettus RV; Rane SG; Grana X; Litvin J; Reddy EP. 2005. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 65(22):10174-8. [PubMed: 16288002]  [MGI Ref ID J:103411]

Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice Cancer Res 60(13):3569-76. [PubMed: 10910070]  [MGI Ref ID J:63566]

Ritland SR; Rowse GJ; Chang Y; Gendler SJ. 1997. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res 57(16):3520-5. [PubMed: 9270023]  [MGI Ref ID J:72134]

Rolla S; Nicolo C; Malinarich S; Orsini M; Forni G; Cavallo F; Ria F. 2006. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 177(11):7626-33. [PubMed: 17114432]  [MGI Ref ID J:120600]

Rovero S; Boggio K; Carlo ED; Amici A; Quaglino E; Porcedda P; Musiani P; Forni G. 2001. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Ther 8(6):447-52. [PubMed: 11313823]  [MGI Ref ID J:69224]

Rowse GJ; Ritland SR; Gendler SJ. 1998. Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis. Cancer Res 58(12):2675-9. [PubMed: 9635596]  [MGI Ref ID J:48749]

Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM. 1998. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res 58(23):5500-6. [PubMed: 9850086]  [MGI Ref ID J:51367]

Sacco MG; Soldati S; Indraccolo S; Cato EM; Cattaneo L; Scanziani E; Vezzoni P. 2003. Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer. Gene Ther 10(22):1903-9. [PubMed: 14502219]  [MGI Ref ID J:86083]

Sacco MG; Soldati S; Mira Cato E; Cattaneo L; Pratesi G; Scanziani E; Vezzoni P. 2002. Combined effects on tumor growth and metastasis by anti-estrogenic and antiangiogenic therapies in MMTV-neu mice. Gene Ther 9(19):1338-41. [PubMed: 12224018]  [MGI Ref ID J:79069]

Schug TT; Berry DC; Toshkov IA; Cheng L; Nikitin AY; Noy N. 2008. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci U S A 105(21):7546-51. [PubMed: 18495924]  [MGI Ref ID J:136361]

Sfondrini L; Rodolfo M; Singh M; Colombo MP; Colnaghi MI; Menard S; Balsari A. 2000. Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice. Cancer Res 60(14):3777-81. [PubMed: 10919650]  [MGI Ref ID J:63663]

Shepherd TG; Kockeritz L; Szrajber MR; Muller WJ; Hassell JA. 2001. The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol 11(22):1739-48. [PubMed: 11719215]  [MGI Ref ID J:72998]

Shyamala G; Chou YC; Cardiff RD; Vargis E. 2006. Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. Cancer Res 66(21):10391-8. [PubMed: 17079459]  [MGI Ref ID J:114913]

Siegel PM; Dankort DL; Hardy WR; Muller WJ. 1994. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14(11):7068-77. [PubMed: 7935422]  [MGI Ref ID J:72127]

Simpson PT; Shoker BS; Barraclough R; Halliwell N; Rudland PS; Sibson DR; Davies MP. 2003. Examination of tumour histopathology and gene expression in a neu/S100A4 transgenic model of metastatic breast cancer. Int J Exp Pathol 84(4):173-83. [PubMed: 14632631]  [MGI Ref ID J:87020]

Smolen GA; Muir B; Mohapatra G; Barmettler A; Kim WJ; Rivera MN; Haserlat SM; Okimoto RA; Kwak E; Dahiya S; Garber JE; Bell DW; Sgroi DC; Chin L; Deng CX; Haber DA. 2006. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res 66(7):3452-5. [PubMed: 16585167]  [MGI Ref ID J:108217]

Subbaramaiah K; Howe LR; Port ER; Brogi E; Fishman J; Liu CH; Hla T; Hudis C; Dannenberg AJ. 2006. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 66(10):5504-11. [PubMed: 16707480]  [MGI Ref ID J:109047]

Thompson JA; Eades-Perner AM; Ditter M; Muller WJ; Zimmermann W. 1997. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy. Int J Cancer 72(1):197-202. [PubMed: 9212243]  [MGI Ref ID J:41380]

Trimble MS; Xin JH; Guy CT; Muller WJ; Hassell JA. 1993. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas. Oncogene 8(11):3037-42. [PubMed: 7692372]  [MGI Ref ID J:72260]

Trimboli AJ; Fukino K; de Bruin A; Wei G; Shen L; Tanner SM; Creasap N; Rosol TJ; Robinson ML; Eng C; Ostrowski MC; Leone G. 2008. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68(3):937-45. [PubMed: 18245497]  [MGI Ref ID J:131862]

VanLith ML; Kohlgraf KG; Sivinski CL; Tempero RM; Hollingsworth MA. 2002. MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses. Int Immunol 14(8):873-82. [PubMed: 12147624]  [MGI Ref ID J:113544]

Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT. 2003. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 171(4):2161-9. [PubMed: 12902523]  [MGI Ref ID J:85703]

Worschech A; Kmieciak M; Knutson KL; Bear HD; Szalay AA; Wang E; Marincola FM; Manjili MH. 2008. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 68(7):2436-46. [PubMed: 18381452]  [MGI Ref ID J:133301]

Yang X; Edgerton SM; Kosanke SD; Mason TL; Alvarez KM; Liu N; Chatterton RT; Liu B; Wang Q; Kim A; Murthy S; Thor AD. 2003. Hormonal and Dietary Modulation of Mammary Carcinogenesis in Mouse Mammary Tumor Virus-c-erbB-2 Transgenic Mice. Cancer Res 63(10):2425-33. [PubMed: 12750262]  [MGI Ref ID J:83495]

Yang YA; Dukhanina O; Tang B; Mamura M; Letterio JJ; MacGregor J; Patel SC; Khozin S; Liu ZY; Green J; Anver MR; Merlino G; Wakefield LM. 2002. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109(12):1607-15. [PubMed: 12070308]  [MGI Ref ID J:77155]

Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS. 2001. Cooperating Oncogenic Events in Murine Mammary Tumorigenesis: Assessment of ErbB2, Mutant p53, and Mouse Mammary Tumor Virus. Exp Mol Pathol 70(3):183-93. [PubMed: 11417997]  [MGI Ref ID J:70644]

Zhang X; Podsypanina K; Huang S; Mohsin SK; Chamness GC; Hatsell S; Cowin P; Schiff R; Li Y. 2005. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene 24(26):4220-31. [PubMed: 15824740]  [MGI Ref ID J:99546]

Zhou H; Chen Wd; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL. 2001. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice. Oncogene 20(42):6009-17. [PubMed: 11593408]  [MGI Ref ID J:72290]

Zhou H; Liu L; Lee K; Qin X; Grasso AW; Kung HJ; Willis JE; Kern J; Wagner T; Gerson SL. 2002. Lung tumorigenesis associated with erb-B-2 and erb-B-3 overexpression in human erb-B-3 transgenic mice is enhanced by methylnitrosourea. Oncogene 21(57):8732-40. [PubMed: 12483526]  [MGI Ref ID J:80974]

Zinser GM; Welsh J. 2004. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis 25(12):2361-72. [PubMed: 15333467]  [MGI Ref ID J:94402]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX1

Colony Maintenance

Mating SystemHomozygote x Homozygote         (Female x Male)
Diet Information LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Pricing for USA, Canada and Mexico shipping destinations View International pricing
Weeks of AgePrice*GenderGenotypes Provided
3-5 weeks $68.10Female or MaleHomozygous for Tg(MMTVneu)202Mul
6 weeks $72.00Female or MaleHomozygous for Tg(MMTVneu)202Mul
7 weeks $75.90Female or MaleHomozygous for Tg(MMTVneu)202Mul
8 weeks $79.80Female or MaleHomozygous for Tg(MMTVneu)202Mul
9 weeks $83.70Female or MaleHomozygous for Tg(MMTVneu)202Mul
10 weeks $87.60Female or MaleHomozygous for Tg(MMTVneu)202Mul
11 weeks $91.50Female or MaleHomozygous for Tg(MMTVneu)202Mul
12 weeks $95.40Female or MaleHomozygous for Tg(MMTVneu)202Mul
Pairs /Price*Pair Genotype
$144.00Homozygous for Tg(MMTVneu)202Mul x Homozygous for Tg(MMTVneu)202Mul
*Price(s) in US dollars ($)

Additional Supply Details

Supply Notes

Pricing for International shipping destinations View USA Canada and Mexico pricing
Weeks of AgePrice*GenderGenotypes Provided
3-5 weeks $88.60Female or MaleHomozygous for Tg(MMTVneu)202Mul
6 weeks $93.70Female or MaleHomozygous for Tg(MMTVneu)202Mul
7 weeks $98.80Female or MaleHomozygous for Tg(MMTVneu)202Mul
8 weeks $103.90Female or MaleHomozygous for Tg(MMTVneu)202Mul
9 weeks $109.00Female or MaleHomozygous for Tg(MMTVneu)202Mul
10 weeks $114.10Female or MaleHomozygous for Tg(MMTVneu)202Mul
11 weeks $119.20Female or MaleHomozygous for Tg(MMTVneu)202Mul
12 weeks $124.30Female or MaleHomozygous for Tg(MMTVneu)202Mul
Pairs /Price*Pair Genotype
$187.20Homozygous for Tg(MMTVneu)202Mul x Homozygous for Tg(MMTVneu)202Mul
*Price(s) in US dollars ($)

Additional Supply Details

Supply Notes

Supply Details

Standard SupplyLevel 3. Up to 50 mice. Larger quantities or custom orders arranged upon request.
Supply Notes
  • Shipped at a specific age in weeks. Mice at a precise age in days, littermates and retired breeders are also available.
  • Strains that must be genotyped are not available until five to seven weeks of age.
  • This strain is included in the Induced Mutant Resource Colony collection.

Control Information

  Control
   001800 FVB/NJ
   FVB/NJ (Stock No. 001800) mice may be used as controls.
 
  Considerations for Choosing Controls
  USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
  International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions


See Terms of Use


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering and Purchasing Information

      Purchasing Information
      JAX® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


OncoMouse® requires a license from DuPont, see Licenses for Strains with OncoMouse® Technology.

Contact information

General inquiries

Contracts Administration

phone:207-288-6470
fax:207-288-6655

JAX® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.


(3.2)